U.S. Drug Supply Chain Integrity: Protecting Patient Safety CDR Connie Jung, PharmD, PhD LCDR Eleni...
-
Upload
anahi-chesbrough -
Category
Documents
-
view
220 -
download
1
Transcript of U.S. Drug Supply Chain Integrity: Protecting Patient Safety CDR Connie Jung, PharmD, PhD LCDR Eleni...
![Page 1: U.S. Drug Supply Chain Integrity: Protecting Patient Safety CDR Connie Jung, PharmD, PhD LCDR Eleni Anagnostiadis, RPh Office of Drug Security, Integrity,](https://reader035.fdocuments.us/reader035/viewer/2022062322/56649ca35503460f94963d06/html5/thumbnails/1.jpg)
U.S. Drug Supply Chain Integrity:U.S. Drug Supply Chain Integrity: Protecting Patient SafetyProtecting Patient Safety
CDR Connie Jung, PharmD, PhDLCDR Eleni Anagnostiadis, RPhOffice of Drug Security, Integrity, and RecallsOffice of Compliance/Center for Drug Evaluation and ResearchU.S. Food and Drug Administration
USPHS Scientific and Training Symposium June 21, 2012
![Page 2: U.S. Drug Supply Chain Integrity: Protecting Patient Safety CDR Connie Jung, PharmD, PhD LCDR Eleni Anagnostiadis, RPh Office of Drug Security, Integrity,](https://reader035.fdocuments.us/reader035/viewer/2022062322/56649ca35503460f94963d06/html5/thumbnails/2.jpg)
2
Objectives
At the end of this session participants will be able to:
1) Describe the threats and vulnerabilities of the pharmaceutical supply chain, such as counterfeiting, diversion, and cargo theft.
2) Identify initiatives undertaken by FDA to ensure that patients receive quality prescription medications.
3) Define the pharmacist's role in educating patients how to identify and report suspect counterfeit or other substandard drug issues.
![Page 3: U.S. Drug Supply Chain Integrity: Protecting Patient Safety CDR Connie Jung, PharmD, PhD LCDR Eleni Anagnostiadis, RPh Office of Drug Security, Integrity,](https://reader035.fdocuments.us/reader035/viewer/2022062322/56649ca35503460f94963d06/html5/thumbnails/3.jpg)
3
Agenda• Overview of Pharmaceutical Supply Chain
• Supply Chain Risks– Counterfeit Drugs
– Diverted Drugs
– Cargo Theft
– Internet Pharmacies
• Current FDA action – Office of Drug Security, Integrity, and Recalls
– Response to Counterfeit Avastin and Altuzan Incidents
– Operation Pangea IV
• Pharmacist’s Role
![Page 4: U.S. Drug Supply Chain Integrity: Protecting Patient Safety CDR Connie Jung, PharmD, PhD LCDR Eleni Anagnostiadis, RPh Office of Drug Security, Integrity,](https://reader035.fdocuments.us/reader035/viewer/2022062322/56649ca35503460f94963d06/html5/thumbnails/4.jpg)
4
Finished dosage form or API
API and Inactive Ingredients
Patient
Intentional Adulteration
Counterfeit
Unknown threats
Terrorism
Globalization
Terrorism
Cargo theft
Diversion
Counterfeit
Unknown threats
ManufacturerImporter
Wholesaler
ManufacturerWholesalerPharmacy
Threats Throughout the Drug Supply ChainThreats Throughout the Drug Supply Chain
Globalization
![Page 5: U.S. Drug Supply Chain Integrity: Protecting Patient Safety CDR Connie Jung, PharmD, PhD LCDR Eleni Anagnostiadis, RPh Office of Drug Security, Integrity,](https://reader035.fdocuments.us/reader035/viewer/2022062322/56649ca35503460f94963d06/html5/thumbnails/5.jpg)
5
Distributor (Primary)Pharmacy
Manufacturer
Distributor (Secondary)Repackager
Complexity of the supply chain is increased by:
– Multiple participants
– Globalization of supply chains
– Criminal activities such as diversion, cargo theft, and counterfeiting
– Rules that vary by state
Example of vulnerabilities in the supply chain:
– Stolen products reintroduced
– Counterfeit/falsified drugs sold to suppliers
– Diverted drugs resold
– Other adulterated/misbranded drugs introduced
Supply Chain for Finished Drugs
![Page 6: U.S. Drug Supply Chain Integrity: Protecting Patient Safety CDR Connie Jung, PharmD, PhD LCDR Eleni Anagnostiadis, RPh Office of Drug Security, Integrity,](https://reader035.fdocuments.us/reader035/viewer/2022062322/56649ca35503460f94963d06/html5/thumbnails/6.jpg)
6
Distributor (Primary)Pharmacy
Manufacturer
Distributor (Secondary)Repackager
Complexity of the supply chain is increased by:
– Multiple participants
– Globalization of supply chains
– Criminal activities such as diversion, cargo theft, and counterfeiting
– Rules that vary by state
Example of vulnerabilities in the supply chain:
– Stolen products reintroduced
– Counterfeit/falsified drugs sold to suppliers
– Diverted drugs resold
– Other adulterated/misbranded drugs introduced
Supply Chain for Finished Drugs
Vulnerabilities/Threats
![Page 7: U.S. Drug Supply Chain Integrity: Protecting Patient Safety CDR Connie Jung, PharmD, PhD LCDR Eleni Anagnostiadis, RPh Office of Drug Security, Integrity,](https://reader035.fdocuments.us/reader035/viewer/2022062322/56649ca35503460f94963d06/html5/thumbnails/7.jpg)
7
Public Health Concerns
Public health risk created by:
• Introduction of stolen product into the legitimate supply chain
• Resurfacing of product many months or years after the theft
• Improper Storage
• Expired Products
• Dilution and adulteration
• Counterfeiting
• Importation
![Page 8: U.S. Drug Supply Chain Integrity: Protecting Patient Safety CDR Connie Jung, PharmD, PhD LCDR Eleni Anagnostiadis, RPh Office of Drug Security, Integrity,](https://reader035.fdocuments.us/reader035/viewer/2022062322/56649ca35503460f94963d06/html5/thumbnails/8.jpg)
8
Compromised Integrity:Examples of Supply Chain Threats
• Counterfeit drugs
• Diverted drugs
• Cargo Theft/ Stolen drugs
![Page 9: U.S. Drug Supply Chain Integrity: Protecting Patient Safety CDR Connie Jung, PharmD, PhD LCDR Eleni Anagnostiadis, RPh Office of Drug Security, Integrity,](https://reader035.fdocuments.us/reader035/viewer/2022062322/56649ca35503460f94963d06/html5/thumbnails/9.jpg)
9
Recent Counterfeit Drugs
• Counterfeit Adderall
• Counterfeit Avastin
• Counterfeit Altuzan
CounterfeitCounterfeit
![Page 10: U.S. Drug Supply Chain Integrity: Protecting Patient Safety CDR Connie Jung, PharmD, PhD LCDR Eleni Anagnostiadis, RPh Office of Drug Security, Integrity,](https://reader035.fdocuments.us/reader035/viewer/2022062322/56649ca35503460f94963d06/html5/thumbnails/10.jpg)
10
95
116
21
27 30
58
32
54
31
56
6572
59
0
10
20
30
40
50
60
70
80
Number of cases
1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011
Year
Counterfeit Drug Cases Opened by FDA’s Office of Criminal Investigations per Fiscal Year
![Page 11: U.S. Drug Supply Chain Integrity: Protecting Patient Safety CDR Connie Jung, PharmD, PhD LCDR Eleni Anagnostiadis, RPh Office of Drug Security, Integrity,](https://reader035.fdocuments.us/reader035/viewer/2022062322/56649ca35503460f94963d06/html5/thumbnails/11.jpg)
11
Diverted DrugsDiverted Drugs
• The sale of drugs outside of the distribution channels for which they were originally intended
• Can originate domestically or internationally
• Counterfeiting is usually associated with a diversion scheme
Reselling of Rx drugs obtained by doctorsReselling of Rx drugs obtained by doctors
![Page 12: U.S. Drug Supply Chain Integrity: Protecting Patient Safety CDR Connie Jung, PharmD, PhD LCDR Eleni Anagnostiadis, RPh Office of Drug Security, Integrity,](https://reader035.fdocuments.us/reader035/viewer/2022062322/56649ca35503460f94963d06/html5/thumbnails/12.jpg)
12
Cargo Theft/Stolen Drugs Cargo Theft/Stolen Drugs
multiple adverse event reports of patients who suffered multiple adverse event reports of patients who suffered poor glycemic control after using a vial from a stolen lotpoor glycemic control after using a vial from a stolen lot
![Page 13: U.S. Drug Supply Chain Integrity: Protecting Patient Safety CDR Connie Jung, PharmD, PhD LCDR Eleni Anagnostiadis, RPh Office of Drug Security, Integrity,](https://reader035.fdocuments.us/reader035/viewer/2022062322/56649ca35503460f94963d06/html5/thumbnails/13.jpg)
13
• Problems with current ‘buying online’ practices
– High volume
– Vast scope
– Unknown origin
• Drug quality concerns
– Lack of “sameness”
– Counterfeits or not FDA-approved
– Potentially confusing names
• Websites
– Misleading (fake online pharmacies, counterfeit products, false health claims)
• How patients can buy drugs online safely (www.fda.gov/buyonline)
Internet – Illegitimate Drug Sellers Internet – Illegitimate Drug Sellers
![Page 14: U.S. Drug Supply Chain Integrity: Protecting Patient Safety CDR Connie Jung, PharmD, PhD LCDR Eleni Anagnostiadis, RPh Office of Drug Security, Integrity,](https://reader035.fdocuments.us/reader035/viewer/2022062322/56649ca35503460f94963d06/html5/thumbnails/14.jpg)
14
![Page 15: U.S. Drug Supply Chain Integrity: Protecting Patient Safety CDR Connie Jung, PharmD, PhD LCDR Eleni Anagnostiadis, RPh Office of Drug Security, Integrity,](https://reader035.fdocuments.us/reader035/viewer/2022062322/56649ca35503460f94963d06/html5/thumbnails/15.jpg)
15
![Page 16: U.S. Drug Supply Chain Integrity: Protecting Patient Safety CDR Connie Jung, PharmD, PhD LCDR Eleni Anagnostiadis, RPh Office of Drug Security, Integrity,](https://reader035.fdocuments.us/reader035/viewer/2022062322/56649ca35503460f94963d06/html5/thumbnails/16.jpg)
16
New Office of Drug Security, Integrity, and Recalls (ODSIR)• Enhanced and targeted resources
• Address increasing supply chain threats
– Intentional adulteration, cargo theft, counterfeiting, diversion, other
– Focus on life-cycle of the product from drug components through to the finished dosage from delivered to the patient
• New and coordinated approaches, policies and enforcement strategies
Recalls
Drug Shortages
Imports
Exports
Drug Supply Chain Integrity
![Page 17: U.S. Drug Supply Chain Integrity: Protecting Patient Safety CDR Connie Jung, PharmD, PhD LCDR Eleni Anagnostiadis, RPh Office of Drug Security, Integrity,](https://reader035.fdocuments.us/reader035/viewer/2022062322/56649ca35503460f94963d06/html5/thumbnails/17.jpg)
17
FDA Supply Chain Security Initiatives
• Response to recent Counterfeit Avastin and Altuzan incidents
• Operation Pangea
![Page 18: U.S. Drug Supply Chain Integrity: Protecting Patient Safety CDR Connie Jung, PharmD, PhD LCDR Eleni Anagnostiadis, RPh Office of Drug Security, Integrity,](https://reader035.fdocuments.us/reader035/viewer/2022062322/56649ca35503460f94963d06/html5/thumbnails/18.jpg)
18
![Page 19: U.S. Drug Supply Chain Integrity: Protecting Patient Safety CDR Connie Jung, PharmD, PhD LCDR Eleni Anagnostiadis, RPh Office of Drug Security, Integrity,](https://reader035.fdocuments.us/reader035/viewer/2022062322/56649ca35503460f94963d06/html5/thumbnails/19.jpg)
19
• Sent to medical practices in the U.S.
• Warned against the use of counterfeit Avastin
• Risks of purchasing from foreign sources
• Quality Specialty Products (QSP)
• Volunteer Distribution
• Report adverse events to MedWatch
Letters from FDA
![Page 20: U.S. Drug Supply Chain Integrity: Protecting Patient Safety CDR Connie Jung, PharmD, PhD LCDR Eleni Anagnostiadis, RPh Office of Drug Security, Integrity,](https://reader035.fdocuments.us/reader035/viewer/2022062322/56649ca35503460f94963d06/html5/thumbnails/20.jpg)
20
Avastin.
•Authentic Avastin marketed by Genentech was not subject to counterfeiting
•Only FDA-approved Avastin for use in U.S
•Considered as safe and effective for intended uses
•Patients that received Genentech Avastin did not need to be concerned
•Counterfeit was a fake of foreign approved version
(Images from Genentech)
![Page 21: U.S. Drug Supply Chain Integrity: Protecting Patient Safety CDR Connie Jung, PharmD, PhD LCDR Eleni Anagnostiadis, RPh Office of Drug Security, Integrity,](https://reader035.fdocuments.us/reader035/viewer/2022062322/56649ca35503460f94963d06/html5/thumbnails/21.jpg)
21
Counterfeit Altuzan
• Altuzan® 400mg/16mL vial with lot number B6021
• Vial contains no active ingredient
• Writing is in English
![Page 22: U.S. Drug Supply Chain Integrity: Protecting Patient Safety CDR Connie Jung, PharmD, PhD LCDR Eleni Anagnostiadis, RPh Office of Drug Security, Integrity,](https://reader035.fdocuments.us/reader035/viewer/2022062322/56649ca35503460f94963d06/html5/thumbnails/22.jpg)
22
![Page 23: U.S. Drug Supply Chain Integrity: Protecting Patient Safety CDR Connie Jung, PharmD, PhD LCDR Eleni Anagnostiadis, RPh Office of Drug Security, Integrity,](https://reader035.fdocuments.us/reader035/viewer/2022062322/56649ca35503460f94963d06/html5/thumbnails/23.jpg)
2323
Global Collaborations – tackling internet
Operation Pangea IV
- INTERPOL led global operation targeting internet websites supplying illegal and dangerous drugs;
- 81 countries participated
- 13,500 websites shutdown
- Approximately 8,000 packages seized
- 2.4 million illicit counterfeit pills confiscated
![Page 24: U.S. Drug Supply Chain Integrity: Protecting Patient Safety CDR Connie Jung, PharmD, PhD LCDR Eleni Anagnostiadis, RPh Office of Drug Security, Integrity,](https://reader035.fdocuments.us/reader035/viewer/2022062322/56649ca35503460f94963d06/html5/thumbnails/24.jpg)
24
• Minimize the risk of and exposure to counterfeit medical products– Know who you are doing business with
• Be vigilant– Inspect the product and packaging– Consider counterfeits if patient complains of:
• New/unusual side effects; lack of therapeutic effect; abnormal taste or smell; pain, burning, or redness at injection site
• Counseling patients about counterfeit medical products– Encourage patients to shop only at pharmacies licensed by the state board of pharmacy– Tell patient if you dispense a drug that may look different from their previously dispensed
drug– If cost is an issue, counsel on assistance program and generics, rather than buying online– Explain the dangers of buying drug online
• Report Suspect Counterfeit medical products to
Pharmacist’s RolePharmacist’s Role
![Page 25: U.S. Drug Supply Chain Integrity: Protecting Patient Safety CDR Connie Jung, PharmD, PhD LCDR Eleni Anagnostiadis, RPh Office of Drug Security, Integrity,](https://reader035.fdocuments.us/reader035/viewer/2022062322/56649ca35503460f94963d06/html5/thumbnails/25.jpg)
25
Resources
ODSIR Drug Integrity and Supply Chain Security www.fda.gov/Drugs/DrugSafety/DrugIntegrityandSupplyChainSecurity/default.htm
Counterfeit Medicine
www.fda.gov/counterfeit
Buying Medicines Online
www.fda.gov/buyonline
Resources
![Page 26: U.S. Drug Supply Chain Integrity: Protecting Patient Safety CDR Connie Jung, PharmD, PhD LCDR Eleni Anagnostiadis, RPh Office of Drug Security, Integrity,](https://reader035.fdocuments.us/reader035/viewer/2022062322/56649ca35503460f94963d06/html5/thumbnails/26.jpg)
26
Thank you
CDR Connie Jung, RPh, PhDActing Associate Director for Policy and [email protected]
LCDR Eleni Anagnostiadis, RPhDivision of Supply Chain [email protected]
Office of Drug Security, Integrity & Recalls Center for Drug Evaluation and ResearchU.S. Food and Drug Administration
Thank You!